

Criteria-Based Consultation Prescribing Program

CRITERIA FOR DRUG COVERAGE

Xanomeline and Trospium (Cobenfy)

Notes:

- Quantity Limits: Yes
- ^ Adequate trial is defined as 2 week period without clinically significant improvement in target symptoms or side effects related to dosage form that cannot be resolved by adjusting dose or timing
- * Intolerance excludes adverse drug reactions that are expected, mild in nature, resolve with continued treatment, and do not require medication discontinuation

Non-Formulary **xanomeline and trospium (Cobenfy)** requires a clinical review. Appropriateness of therapy will be based on the following criteria:

Initiation (new start) criteria: Non-Formulary **xanomeline and trospium (Cobenfy)** will be covered on the prescription drug benefit when the following criteria are met:

- Prescribed by Psychiatry
- Patient has a diagnosis of schizophrenia or schizoaffective disorder
- Patient is age 18 years or older
- Patient has failed an adequate trial[^] of 2 antipsychotics or patient has an allergy or intolerance* to 2 formulary antipsychotic agents (e.g. quetiapine, risperidone, olanzapine, aripiprazole, ziprasidone, clozapine, or a first-generation antipsychotic)
- Psychiatrist has considered and discussed clozapine with the patient

Criteria for current Kaiser Permanente members already taking the medication who have not been reviewed previously: Non-Formulary **xanomeline and trospium (Cobenfy)** will be covered on the prescription drug benefit when the following criteria are met:

- Prescribed by Psychiatry
- Patient has a diagnosis of schizophrenia or schizoaffective disorder
- Patient is age 18 years or older
- Patient has failed an adequate trial[^] of 2 antipsychotics or patient has an allergy or intolerance* to 2 formulary antipsychotic agents (e.g. quetiapine, risperidone, olanzapine, aripiprazole, ziprasidone, clozapine, or a first-generation antipsychotic)
- Psychiatrist has considered and discussed clozapine with the patient

Criteria-Based Consultation Prescribing Program

CRITERIA FOR DRUG COVERAGE

Xanomeline and Trospium (Cobenfy)

Criteria for *new members entering Kaiser Permanente already taking the medication who have not been reviewed previously*: Non-Formulary xanomeline and trospium (Cobenfy) will be covered on the prescription drug benefit when the following criteria are met:

- Patient has a diagnosis of schizophrenia or schizoaffective disorder

kp.org

Revised: 12/12/24
Effective: 02/20/25

All plans offered and underwritten by
Kaiser Foundation Health Plan of the Northwest